Reliability and Validity of Sensor-derived Measurements in Individuals With Parkinson's Disease: Preliminary Results From the INERTIAL Study (INERTIAL)
Parkinson's disease (PD) is a neurodegenerative disorder that affects a significant portion of the elderly population. Gait disturbance is a core symptom of the disease and can impact stride length and height, gait speed, trunk sway, and the pendular movement of the arms. This impairment is often accompanied by postural alterations, balance difficulties, and an increased risk of falls. Additionally, freezing and festination phenomena may also occur.
Inertial Movement Units are inertial sensors that are used for monitoring clinical and identification of movement biomarkers in patients with neurodegenerative diseases. In particular, among existing devices based on IMUs, prototype versions of SensMode have shown promising results in identifying objective indices to support diagnosis and monitoring in patients with PD. Recent work shows that the aforementioned wearable sensors during some tasks of the MDS-UPDRS have excellent discriminative property between subjects healthy and those with PD.
The aim of the present research project is to investigate the potential of sensors in measuring limb movement in subjects with Parkinson's Disease.
調査の概要
状態
条件
詳細な説明
In detail, the primary objective of this project is to evaluate the reliability of measurements obtained from sensors used for measuring limb movement in subjects with PD. Specifically, the inter-rater and intra-rater reliability of measurements recorded with inertial sensor, during the execution of some items of Section III of the MDS-UPDRS. In addition, the study aims to assess the validity of the measurements obtained from the inertial sensor set by comparing them with clinical data in a sample of patients with PD.
Specifically, the objectives of the study are as follows:
- The verification of the reliability of sensor-derived measurements; in particular, the inter-rater and intra-rater reliability of measurements recorded with inertial sensor, while performing of some items of Section III of the MDS-UPDRS.
- The verification of the validity (criterion validity) of the experimental device-derived measurements during the execution of the items of Section III of the MDS-UPDRS involving limbs.
The data to be collected will include: demographic variables, clinical variables (Montreal Cognitive Assessment - MoCA; Clinical Instability Scale - CIS; Hoehn and Yahr stage - H&Y; MDS-UPDRS Part III), instrumental variables (recorded by inertial sensors). Inclusion criteria for participant selection are: age over 18 years, diagnosis of PD according to the Postuma criteria, Hoehn and Yahr stages I-IV, and signed informed consent. Exclusion criteria include: presence of severe comorbidities, significant cognitive impairment, or signs of clinical instability.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
FI
-
Florence、FI、イタリア、50134
- Dipartimento di Medicina Sperimentale e Clinica
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Age greater than or equal to 18 years
- Diagnosis of Parkinson's disease (PD) according to Postuma criteria
- Hoehn and Yahr stages I-IV
- Signed informed consent provided by the participant or, when necessary, by a legal guardian or court-appointed representative
Exclusion Criteria:
- Severe comorbid conditions that may alter the subject's motor function
- Cognitive impairment severe enough to prevent cooperation during the execution of the protocol
- Presence of clinical instability, defined as a score greater than zero on the Clinical Instability Scale (CIS)
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Patients with Parkinson disease diagnosis
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Participants assessed by BMR4Inertial wearable inertial sensor system
時間枠：Baseline
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III) motor examination is acquired using the BMR4Inertial wearable inertial sensor system. The following MDS-UPDRS Part III items are assessed through the experimental setup: finger tapping, hand movements, pronation-supination movements of the hands, toe tapping, leg agility, arising from chair, gait, postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, and constancy of rest tremor. Raw inertial signals are acquired using wearable sensors and processed to obtain quantitative sensor-derived measures of motor performance. |
Baseline
|
|
MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
時間枠：At least 15 minutes after baseline
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III) motor examination is acquired using the BMR4Inertial wearable inertial sensor system. The following MDS-UPDRS Part III items are assessed through the experimental setup: finger tapping, hand movements, pronation-supination movements of the hands, toe tapping, leg agility, arising from chair, gait, postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, and constancy of rest tremor. Raw inertial signals are acquired using wearable sensors and processed to obtain quantitative sensor-derived measures of motor performance. |
At least 15 minutes after baseline
|
|
Participants assessed by BMR4Inertial wearable inertial sensor system
時間枠：At least 30 minutes after baseline
|
The Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III) motor examination is acquired using the BMR4Inertial wearable inertial sensor system. The following MDS-UPDRS Part III items are assessed through the experimental setup: finger tapping, hand movements, pronation-supination movements of the hands, toe tapping, leg agility, arising from chair, gait, postural tremor of the hands, kinetic tremor of the hands, rest tremor amplitude, and constancy of rest tremor. Raw inertial signals are acquired using wearable sensors and processed to obtain quantitative sensor-derived measures of motor performance. |
At least 30 minutes after baseline
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Demographic variables
時間枠：Baseline
|
Date of Parkinson's diagnosis, age, education level, sex, most affected side
|
Baseline
|
|
The Montreal Cognitive Assessment Test - MoCA
時間枠：Baseline
|
The Montreal Cognitive Assessment (MoCA) is a screening tool that evaluates multiple cognitive domains, including attention, visuoconstructive abilities, memory, language, executive functions, numeracy, and orientation. It has been validated for the assessment of cognitive impairment in individuals with Parkinson's disease. Scores range from 0 to 30, with higher scores indicating better cognitive function. |
Baseline
|
|
Scale of clinical instability - SIC
時間枠：Baseline
|
it is a rapid-response scale used to test the degree of clinical instability.
It has a score ranging from 0-5 where 0 indicates a condition requiring clinical monitoring of more than 60 days and 5 a multi-day monitoring
|
Baseline
|
|
Hoehn e Yahr scale
時間枠：Baseline
|
it is the most commonly used scale to describe the progression of Parkinson's disease.
The modified version of the scale consists of a seven-point scoring distributed over 5 stages of severity where 1 corresponds to a unilateral manifestation of the disease and 5 to wheelchair or bed confinement.
|
Baseline
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。